FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus...

Full description

Bibliographic Details
Main Authors: Michal Stefanik, James J. Valdes, Fortunatus C. Ezebuo, Jan Haviernik, Ikemefuna C. Uzochukwu, Martina Fojtikova, Jiri Salat, Ludek Eyer, Daniel Ruzek
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Microorganisms
Subjects:
FDA
flavivirus
Zika virus
tick-borne encephalitis virus
West Nile virus
antiviral
Online Access:https://www.mdpi.com/2076-2607/8/4/599

Internet

https://www.mdpi.com/2076-2607/8/4/599

Similar Items